Figure 1From: Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studiesKaplan–Meier curve for cumulative event rate for treatment-emergent major and clinically relevant non-major bleeding. VKA, vitamin K antagonist.Back to article page